Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents.

38 PFS was significantly improved with durvalumab plus chemotherapy vs chemotherapy alone (HR: 0.74 [95% CI: 0.62, 0.89]; P=0.0009; median, 5.5 vs 4.8 months, respectively); however, this trend for improved OS did not reach statistical significance (HR: 0.86 [95% CI: 0.72, 1.02]; P=0.0758; median, 13.3 vs 11.7 months, respectively; 24-month OS, 29.6% vs 22.1%, respectively).

also in 111,027 other papers